as soon as is submitted to ZB.
FASEB J. 32, 703-716 (2017)
Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease with limited therapeutic options and unknown etiology. IPF is characterized by epithelial cell injury, impaired cellular crosstalk between epithelial cells and fibroblasts, and the formation of fibroblast foci with increased extracellular matrix deposition (ECM). We investigated the role of runt-related transcription factor 2 (RUNX2), a master regulator of bone development that has been linked to profibrotic signaling. RUNX2 expression was up-regulated in lung homogenates from patients with IPF and in experimental bleomycin-induced lung fibrosis. The RUNX2 level correlated with disease severity as measured by decreased diffusing capacity and increased levels of the IPF biomarker, matrix metalloproteinase 7. Nuclear RUNX2 was observed in prosurfactant protein C-positive hyperplastic epithelial cells and was rarely found in myofibroblasts. We discovered an up-regulation of RUNX2 in fibrotic alveolar epithelial type II (ATII) cells as well as an increase of RUNX2-negative fibroblasts in experimental and human pulmonary fibrosis. Functionally, small interfering RNA-mediated RUNX2 knockdown decreased profibrotic ATII cell function, such as proliferation and migration, whereas fibroblasts displayed activation markers and increased ECM expression after RUNX2 knockdown. This study reveals that RUNX2 is differentially expressed in ATII cells vs. fibroblasts in lung fibrosis, which contributes to profibrotic cell function. Cell-specific targeting of RUNX2 pathways may represent a therapeutic approach for IPF.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
5.498
1.220
9
8
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Runx2 ; Ipf ; Alveolar Epithelial Cells ; Fibroblast; Alveolar Epithelial-cells; Human Lung Fibroblasts; Mesenchymal Transition; Signaling Pathway; Osteoblast Differentiation; Molecular-mechanisms; Gene-expression; Breast-cancer; Beta; Proliferation
Language
english
Publication Year
2017
HGF-reported in Year
2017
ISSN (print) / ISBN
0892-6638
e-ISSN
1530-6860
Journal
FASEB Journal
Quellenangaben
Volume: 32,
Issue: 2,
Pages: 703-716
Publisher
Wiley
Publishing Place
Bethesda, Md.
Reviewing status
Peer reviewed
POF-Topic(s)
30202 - Environmental Health
30203 - Molecular Targets and Therapies
30203 - Molecular Targets and Therapies
Research field(s)
Lung Research
Immune Response and Infection
Immune Response and Infection
PSP Element(s)
G-501600-001
G-501500-004
G-503100-001
G-501500-004
G-503100-001
WOS ID
WOS:000425146900015
Scopus ID
85041668657
PubMed ID
28986417
Erfassungsdatum
2017-10-12